Kezar Life Sciences, Inc. (KZR)

USD 6.29

(-3.53%)

Market Cap (In USD)

45.89 Million

Revenue (In USD)

7 Million

Net Income (In USD)

-101.87 Million

Avg. Volume

516.03 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
5.2-11.4
PE
-
EPS
-
Beta Value
0.217
ISIN
US49372L1008
CUSIP
49372L100
CIK
1645666
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Christopher J. Kirk Ph.D.
Employee Count
-
Website
https://www.kezarlifesciences.com
Ipo Date
2018-06-21
Details
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.